FORA Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

FORA Capital’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-24,971	Closed	-$390K	–	1061
2020 Q4	$390K	Buy	+24,971	New	+$293K	0.06%	338

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

FORA Capital's SGMO Position: Q1 2021 in Review

FORA Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2021, closing a stake of 24,971 shares — an estimated $390K sold.

FORA Capital first reported a position in SGMO in Q4 2020 and held it in 1 quarter. The position peaked at $390K in Q4 2020. 203 funds tracked by Wall St. Rank hold SGMO as of Q1 2021.

FORA Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2021 after selling out during the quarter.
FORA Capital sold 24,971 SANGAMO THERAPEUTICS INC shares in Q1 2021, an estimated $390K.
FORA Capital first reported a position in SANGAMO THERAPEUTICS INC in Q4 2020 and held it in 1 quarter.
FORA Capital's SANGAMO THERAPEUTICS INC position peaked at $390K in Q4 2020.
203 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2021.

Based on FORA Capital's 13F filing for Q1 2021, filed 17 May 2021.